Sangamo Therapeutics downgraded by BofA Securities with a new price target
$SGMO
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
BofA Securities downgraded Sangamo Therapeutics from Buy to Neutral and set a new price target of $5.00 from $8.00 previously